FDA and regulatory enforcement risk
EsoGuard is tied to laboratory-developed test assumptions and regulatory enforcement discretion.
- Scope
- EsoGuard and related diagnostics
- Materiality
- high
PAVmed Inc.
PAVmed Inc. is a U.S.-based life sciences company organized around a portfolio of medical technologies developed through separate operating subsidiaries. Its business includes diagnostic and cancer-care products, with a focus on devices, tests, and related platforms for unmet clinical needs.
−30 564,8 %
−207,0 %
564,8 %
−97,6 %
0.17
0.17
| % | |
|---|---|
| Esophageal cancer screening diagnostics | 55% Non-endoscopic screening and diagnostic tools for Barrett's esophagus and esophageal cancer risk. |
| Cancer care software/platform services | 25% Subscription-based cancer care platform services tied to Veris Health. |
| Medical device commercialization | 10% Development and commercialization of proprietary medical devices and related consumables. |
| Incubator and pipeline development | 10% Early-stage product development and incubation of new healthcare technologies. |
PAVmed sells into the healthcare ecosystem rather than directly to consumers, with demand driven by physicians,...
- Physicians and gastroenterology practicesprimary
They buy or order EsoGuard and use EsoCheck-based workflows to screen at-risk patients for Barrett's esophagus.
- Hospitals and health systemsprimary
They support clinical deployment, patient collection, and research programs around esophageal screening and cancer care.
- Clinical research institutionssecondary
They participate in validation studies and grant-funded trials evaluating EsoCheck and EsoGuard.
- Cancer care organizationssecondary
They use Veris Health platform services for cancer care coordination and related subscription workflows.
PAVmed is headquartered in the United States and its reported operating activity is primarily U.S.-based...
- •Headquartered and primarily operated in the United States
- •Clinical studies and commercialization efforts are U.S.-focused
- •Revenue is tied to U.S. healthcare providers and patients
- •Regulatory exposure is concentrated in the U.S. FDA environment
- •Research partnerships involve U.S. academic medical centers
PAVmed’s strategy is to build and commercialize a portfolio of novel healthcare technologies through a parent-company...
01
Commercialize EsoGuard and EsoCheckshort-term
Clinical adoption depends on evidence, physician acceptance, and workflow integration.
02
Build Veris Health subscription platformmedium-term
Recurring platform revenue can diversify the business beyond single-product diagnostics.
03
Use flexible subsidiary financingshort-term
Capital can be matched to each asset’s development stage and funding needs.
PAVmed depends on successful commercialization of a small number of healthcare assets, so adoption, reimbursement, and...
Commercial adoption risk
Revenue depends on physicians and healthcare systems adopting new screening and care tools.
- Scope
- EsoGuard, EsoCheck, Veris Health
- Materiality
- high
Financing and dilution risk
The company has used ATM equity sales and convertible/preferred structures to fund operations.
- Scope
- Common stock, preferred stock, convertible notes
- Materiality
- high
Clinical evidence risk
Market acceptance of screening products depends on trial outcomes and published validation.
- Scope
- NIH-backed EsoCheck/EsoGuard study
- Materiality
- medium
Revenue recognition for subscription and diagnostic services
Can create quarter-to-quarter volatility in reported revenue
Fair value measurement of convertible notes and preferred stock
Can materially affect net results without corresponding cash flow
Debt extinguishment accounting
Can distort period-to-period comparability
Equity issuance and dilution
Important for investors modeling ownership dilution
: 29.4.2026